Dupixent is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis and the only approved therapy shown to shrink nasal polyp size and improve the signs and symptoms of the associated chronic rhinosinusitis.
Davy James, Associate Editorial Director
Advertisement
Articles by Davy James, Associate Editorial Director
Advertisement
Latest Updated Articles
A Review of DupilumabPublished: October 27th 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
2
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
3
Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer
4
TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC
5
